Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$8.98 - $11.6 $559,454 - $722,680
-62,300 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$9.38 - $13.63 $50,520 - $73,411
-5,386 Reduced 7.96%
62,300 $606,000
Q4 2020

Feb 02, 2021

SELL
$7.78 - $12.13 $10,114 - $15,769
-1,300 Reduced 1.88%
67,686 $694,000
Q3 2020

Nov 05, 2020

BUY
$9.5 - $11.14 $17,100 - $20,052
1,800 Added 2.68%
68,986 $696,000
Q2 2020

Aug 12, 2020

SELL
$7.01 - $13.24 $13,010 - $24,573
-1,856 Reduced 2.69%
67,186 $701,000
Q1 2020

May 12, 2020

BUY
$6.28 - $14.57 $20,987 - $48,692
3,342 Added 5.09%
69,042 $583,000
Q3 2019

Oct 31, 2019

BUY
$8.75 - $12.85 $75,250 - $110,510
8,600 Added 15.06%
65,700 $707,000
Q2 2019

Aug 15, 2019

SELL
$12.3 - $35.76 $6,150 - $17,880
-500 Reduced 0.87%
57,100 $726,000
Q1 2019

May 03, 2019

SELL
$20.77 - $42.37 $33,232 - $67,792
-1,600 Reduced 2.7%
57,600 $2.23 Million
Q4 2018

Feb 08, 2019

SELL
$20.07 - $46.7 $114,399 - $266,190
-5,700 Reduced 8.78%
59,200 $1.21 Million
Q3 2018

Nov 13, 2018

SELL
$41.2 - $59.85 $222,480 - $323,190
-5,400 Reduced 7.68%
64,900 $2.98 Million
Q2 2018

Aug 15, 2018

SELL
$48.3 - $68.25 $1.69 Million - $2.39 Million
-35,000 Reduced 33.24%
70,300 $4.16 Million
Q1 2018

May 11, 2018

SELL
$59.7 - $99.25 $491,510 - $817,125
-8,233 Reduced 7.25%
105,300 $7.17 Million
Q4 2017

Feb 06, 2018

BUY
$93.85 - $132.45 $519,272 - $732,845
5,533 Added 5.12%
113,533 $11.2 Million
Q3 2017

Nov 15, 2017

BUY
$72.0 - $119.75 $7.78 Million - $12.9 Million
108,000
108,000 $12.9 Million

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $138M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.